ChinaDrugStatus

Tofersen

托夫生
Brand: Qalsody / 凯盛迪·Neurology / Rare Disease·Last verified 2026-11-20

SOD1 antisense oligonucleotide newly added to the 2026 Commercial Health Insurance Innovative Drug List (#25) for adult SOD1-mutated ALS.

China Approval (NMPA)

Approved
Approval Number(s)
国药准字HJ20240102
Initial Approval Date
Sep 26, 2024
Notice Published
Oct 8, 2024
MAH
Biogen MA Inc. (Biogen MA Inc.)
Approved Scope
Conditional approval for adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene.

National Reimbursement

Not Listed

Not included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).

Commercial Insurance List

Announced · Effective Jan 1, 2027
2026 List Entry
#25 · 凯盛迪
Validity Period
2027-01-01 to 2028-12-31
MAH / Authorized Entity
Biogen MA Inc. · 渤健生物科技(上海)有限公司
Listed Indication Scope
Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Catalog inclusion only. Actual reimbursement depends on individual commercial health insurance policy contracts.

Approved Products, Dosage Forms & Approval Numbers

1 verified NMPA record
Approval No.Dosage Form & StrengthEvent & ScopeApproval / Notice DateMAH & Source
国药准字HJ20240102
Injection (注射液)
15ml:0.1g (100mg)
Initial Approval

Conditional approval for adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene.

用于治疗携带超氧化物歧化酶1(SOD1)基因突变的肌萎缩侧索硬化(ALS)成人患者(附条件批准)。

Approved: 2024-09-26
Published: 2024-10-08
Biogen MA Inc.

Change Timeline

  1. (2027-01-01)Commercial List· Catalog published: Nov 14, 2026

    2026 Commercial List · Newly Added (#25)

    Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

    Chinese original: 本品用于治疗携带超氧化物歧化酶1(SOD1)基因突变的肌萎缩侧索硬化(ALS)成人患者。

    NHSA · PDF p.4Verified 2026-11-20
  2. (2024-09-26)NMPA Approval· Notice published: Oct 8, 2024

    NMPA Initial Marketing Approval (国药准字HJ20240102 · 15ml:0.1g (100mg))

    Conditional approval for adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene.

    Chinese original: 用于治疗携带超氧化物歧化酶1(SOD1)基因突变的肌萎缩侧索硬化(ALS)成人患者(附条件批准)。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

托夫生注射液dosage name(NHSA)
Qalsodybrand en(WHO)
凯盛迪brand zh(NHSA)

Primary Sources for This Record